Russia launches first domestic HPV vaccine amid low uptake and silent infections

Russia's first domestic HPV vaccine facility opened in the Kirov Region in autumn 2025. The move marks a major step in tackling widespread infections, with up to 90% of people in areas like Nizhny Novgorod contracting the virus at some point. Despite this, vaccination rates remain low across the country due to limited uptake and cultural barriers. The newly produced vaccine received approval for adults and was authorised for children aged nine and above by January 2026. Health experts strongly recommend childhood immunisation as one of the most effective ways to prevent HPV. Yet, most infections go unnoticed, as around 90% of cases show no symptoms.

Detecting HPV requires PCR testing, but mass screening is not yet available. Once production ramps up, the vaccine is set to be included in Russia's National Immunization Schedule. However, as of March 2026, no reliable data exists on whether the Kirov facility's launch has influenced vaccination rates in Nizhny Novgorod, where uptake remains stubbornly low. The virus's high prevalence contrasts sharply with the slow adoption of preventive measures. Without widespread testing or vaccination, the majority of infections continue to spread undetected.

The domestic HPV vaccine offers a new tool in combating a virus that affects nearly everyone at some stage. Its inclusion in the national immunisation programme could eventually improve protection rates. For now, though, low vaccination coverage and the lack of mass screening leave most infections unchecked.